Methodological concerns, implausibly early fracture reduction, and potential outcome misclassification: Comment on “Comparative effectiveness of romosozumab versus teriparatide for fracture prevention: A new-user, active comparator design”

IF 3.5 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Bone Pub Date : 2025-05-31 DOI:10.1016/j.bone.2025.117547

Soichiro Masuda , Toshiki Fukasawa , Shuichi Matsuda , Koji Kawakami

引用次数: 0

查看原文本刊更多论文

方法学问题，难以置信的早期骨折复位，以及潜在的结果错误分类：对“romosozumab与teriparatide预防骨折的比较有效性：一种新用户，有效的比较设计”的评论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone 医学-内分泌学与代谢

CiteScore

8.90

自引率

4.90%

发文量

264

审稿时长

30 days

期刊介绍： BONE is an interdisciplinary forum for the rapid publication of original articles and reviews on basic, translational, and clinical aspects of bone and mineral metabolism. The Journal also encourages submissions related to interactions of bone with other organ systems, including cartilage, endocrine, muscle, fat, neural, vascular, gastrointestinal, hematopoietic, and immune systems. Particular attention is placed on the application of experimental studies to clinical practice.